Health Care [ 5/12 ] | Health Care Equipment & Supplies [ 40/74 ]
NASDAQ | Common Stock
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide.
It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products.
The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.
It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services.
The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities.
ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | 2.11 Increased by +34.39% | 1.48 Increased by +42.38% |
| Nov 12, 24 | 1.59 Increased by +1.27% | 1.25 Increased by +27.20% |
| Aug 7, 24 | 1.56 Decreased by -17.02% | 1.00 Increased by +56.00% |
| May 7, 24 | 0.96 Decreased by -44.83% | 0.82 Increased by +17.07% |
| Feb 27, 24 | 1.57 Decreased by -1.88% | 1.19 Increased by +31.93% |
| Nov 6, 23 | 1.57 Decreased by -10.29% | 1.39 Increased by +12.95% |
| Aug 7, 23 | 1.88 Increased by +37.23% | 1.60 Increased by +17.50% |
| May 8, 23 | 1.74 Decreased by -4.40% | 1.43 Increased by +21.68% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 629.80 M Increased by +7.11% | -23.83 M Decreased by -38.96% | Decreased by -3.78% Decreased by -29.74% |
| Sep 30, 24 | 589.13 M Increased by +6.47% | -32.98 M Decreased by -555.69% | Decreased by -5.60% Decreased by -527.99% |
| Jun 30, 24 | 596.46 M Increased by +8.58% | -21.41 M Decreased by -115.48% | Decreased by -3.59% Decreased by -98.45% |
| Mar 31, 24 | 565.96 M Decreased by -0.47% | -39.47 M Decreased by -302.27% | Decreased by -6.97% Decreased by -304.19% |
| Dec 31, 23 | 587.99 M Increased by +1.73% | -17.15 M Decreased by -10.37% | Decreased by -2.92% Decreased by -8.50% |
| Sep 30, 23 | 553.31 M Decreased by -7.45% | 7.24 M Increased by +154.80% | Increased by +1.31% Increased by +159.21% |
| Jun 30, 23 | 549.31 M Decreased by -2.08% | -9.93 M Decreased by -32.91% | Decreased by -1.81% Decreased by -35.74% |
| Mar 31, 23 | 568.65 M Increased by +4.70% | -9.81 M Increased by +74.23% | Decreased by -1.73% Increased by +75.38% |